Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mirati Therapeutics
(NQ:
MRTX
)
58.70
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirati Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
MRTX Stock Alert: What to Know as Mirati Therapeutics Considers Potential Takeover
November 23, 2022
Mirati Therapeutics (MRTX) stock is a hot topic on Wednesday as the cancer drugmaker considers strategic alternatives, such as a takeover.
Via
InvestorPlace
Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month
November 23, 2022
Mirati Therapeutics Inc (NASDAQ: MRTX) is reportedly amid fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline. For some time, the cancer-focused company...
Via
Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
November 23, 2022
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...
Via
Benzinga
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
November 09, 2022
Biotech stocks were hammered Wednesday, including several that had good news.
Via
Investor's Business Daily
4 Analysts Have This to Say About Mirati Therapeutics
November 09, 2022
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Via
Benzinga
What 4 Analyst Ratings Have To Say About Mirati Therapeutics
October 28, 2022
Over the past 3 months, 4 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
October 28, 2022
Upgrades
Via
Benzinga
4 Analysts Have This to Say About Mirati Therapeutics
September 26, 2022
Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Mirati's Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer
September 08, 2022
Via
Benzinga
4 Biotech Stocks With Huge Incoming Catalysts
October 12, 2022
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Via
The Motley Fool
What 4 Analyst Ratings Have To Say About Mirati Therapeutics
September 26, 2022
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
September 15, 2022
Upgrades
Via
Benzinga
Mirati Therapeutics: Q2 Earnings Insights
August 03, 2022
Mirati Therapeutics (NASDAQ:MRTX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
10 Analysts Have This to Say About Mirati Therapeutics
July 07, 2022
Analysts have provided the following ratings for Mirati Therapeutics (NASDAQ:MRTX) within the last quarter:
Via
Benzinga
Healthcare Sector Still Looks Good But Lacks Momentum
September 06, 2022
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...
Via
Talk Markets
Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost
August 31, 2022
Amgen says Lumakras beat out chemo in patients with non small-cell lung cancer.
Via
Investor's Business Daily
Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday
August 31, 2022
Barnes & Noble Education, Inc. (NYSE: BNED) gained 16.8% to $2.64 after reporting upbeat quarterly sales. Bausch Health Companies Inc. (NYSE: BHC) gained 15.5% to $5.91.
Via
Benzinga
Whither Small Caps After Fed’s Tough Talk?
August 29, 2022
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...
Via
Talk Markets
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
August 15, 2022
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...
Via
Talk Markets
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
August 05, 2022
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
August 08, 2022
Gainers
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
July 13, 2022
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.
Via
Benzinga
Biotech ETF Tops in June: 5 Stocks That Outperform
June 30, 2022
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.
Via
Talk Markets
Bear Market Rally Lifts HealthCare Stocks Off Bottom
June 22, 2022
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
Via
Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 21, 2022
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started!
Via
InvestorPlace
Here's What Cramer Has To Say About Zuora, Johnson Controls International And More
June 13, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Zuora Inc (NYSE: ZUO) is losing money. "It does not fit our criteria of what you should own," he added.
Via
Benzinga
Mid-Afternoon Market Update: Dow Rises 100 Points; Kiromic BioPharma Shares Spike Higher
June 07, 2022
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday.
Via
Benzinga
79 Biggest Movers From Yesterday
June 08, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.